Please login to the form below

Not currently logged in

tax inversion

This page shows the latest tax inversion news and features for those working in and with pharma, biotech and healthcare.

Shire rebuffs Takeda bids, as Allergan bows out

Shire rebuffs Takeda bids, as Allergan bows out

AbbVie offered $55bn for the biopharma in 2014, but the transaction was abandoned after the US introduced new measures to discourage tax inversion deals.

Latest news

More from news
Approximately 7 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    curb tax inversion s.

  • A rare talent A rare talent

    took steps to prevent 'tax inversion' mergers.

  • Deal Watch October 2016 Deal Watch October 2016

    years because of the taxman's changes in tax inversion rules.

  • Deal Watch August 2016 Deal Watch August 2016

    In April this year the major news was the collapse of Pfizer's $160bn acquisition of Allergan as a result of change in US tax regulations to prevent tax inversions. ... This can turn into a hostile bid. For example, Pfizer made an unsolicited bid for

  • Deal Watch April 2016 Deal Watch April 2016

    Pfizer's dogged determination to achieve a tax inversion can only be described as a fiasco and given, that this was the second time of trying, perhaps fiascos, is more appropriate. ... Non US countries where Pfizer have parked $80bn. Non-US target

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...